Trial Profile
Efficacy and safety of switching from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Apr 2017
Price :
$35
*
At a glance
- Drugs Macitentan (Primary) ; Sildenafil
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- 21 Apr 2017 New trial record
- 08 Apr 2017 Primary endpoint of prevalence of patients in WHO functional class III/IV after drug switch has been met, according to results presented at the 37th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
- 08 Apr 2017 Results presented at the 37th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation